Alpha Teknova manufactures critical reagents and laboratory products used in the discovery, development, and commercialization of therapeutics, vaccines, and molecular diagnostics. The company's primary product portfolio includes pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. These products serve as essential inputs in biopharmaceutical research and development workflows.
The company operates through two main business segments: Lab Essentials, which provides chemical formulations for biological research and drug discovery applications, and Clinical Solutions, which offers custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The customer base comprises pharmaceutical and biotechnology companies, contract development and manufacturing organizations (CDMOs), in vitro diagnostic companies, and academic and government research institutions across the United States and internationally.
Founded in 1996 and headquartered in Hollister, California, Alpha Teknova is a publicly traded company on Nasdaq with a market capitalization of approximately $100 million. The company maintains a presence across multiple geographic markets, serving the global life sciences research and development sector.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.57 | $-0.57 | +50.9% | |
| 2023 | $-1.16 | $-1.16 | +31.4% | |
| 2022 | $-1.69 | $-1.69 | -177.0% | |
| 2021 | $-0.61 | $-0.61 | — |